Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP
Go back to Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP| Regeneron (NASDAQ: REGN) | Delayed: 612.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $612.50 | 52 Week Low | $325.35 | |||
| Day High | $612.50 | P/E | 160.76 | |||
| Day Low | $612.50 | EPS | $3.81 | |||
| Volume | 764 | |||||
